【摘要】 目的观察胃癌患者接受卡培他滨及氟尿嘧啶治疗过程中手足综合征(HFS)的发生情况和治疗反应。方法总结2010年1月至2012年12月22例接受卡培他滨联合奥沙利铂及23例5-氟尿嘧啶联合奥沙利铂化疗的患者资料。结果 45例患者中有13例(28.9%)发生HFS,其中Ⅰ度7例(15.6%)、Ⅱ度3例(6.7%)、Ⅲ度2例(4.4%);卡培他滨奥沙利铂治疗组、与奥沙利铂5-氟尿嘧啶组分别有9例(40.9%)、3例(13.0%)、各组间的发病率存在明显差异(卡方检验,P=0.025);Ⅰ度HFS患者都维持卡培他滨剂量,Ⅱ度HFS患者中2例(66.7%)例需减量后完成化疗,Ⅱ度HFS患者中1例,Ⅲ度HFS患者中2例因患者不能耐受中止化疗。结论 HFS是卡培他滨化疗时常见的不良反应,化疗过程种发生率较静脉滴注5-氟尿嘧啶高。发生前应给予预防,如发生后应及时处理HFS,避免皮肤损伤加重,必要时适当减低卡培他滨用量,以使患者能坚持完成预定的化疗周期。更多还原

【Abstract】 Objective To observe the gastric cancer patients receiving capecitabine and 5-fluorouracil in the treatment of hand foot syndrome(HFS) incidence and treatment response. Methods From January to 2012 in 2010 December 22 patients who received data of capecitabine combined with oxaliplatin and fluorouracil plus oxaliplatin chemotherapy in the treatment of 23 cases of 5- fluorouracil. Results In 45 cases, 13 cases(28.9%) had HFS, including 7 cases of type I(15.6%), 3 cases of type II(6.7%), 2 cases(4.4%) of third degree; capecitabine and oxaliplatin, fluorouraciland oxaliplatin in treatment group and 5- fluorouracil group were 9 cases(40.9%), 3 cases(13% the incidence between groups), there were significantly differences(chi square test, P=0.025); first degree HFS patientsmaintain capecitabine dose, second degree HFS in 2 cases(66.7%) patients required reduction after completion of chemotherapy, second degree HFS in 1 cases, HFS in 2 cases of third degree for patients who cannot tolerate discontinued chemotherapy. Conclusion HFS is the most common adverse reactions of capecitabine chemotherapy, chemotherapy for the occurrence of intravenous infusion of 5- fluorouracil high. There should be given before the prevention, such asoccurred after shall timely processing of HFS, avoid skin damage, it is necessary and appropriate to reduce the capecitabine dose, so thatpatients can adhere to complete the chemotherapy cycle scheduled.更多还原